Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register - Wikidata - awgldk - TriplyDB

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

http://www.wikidata.org/entity/Q34110060

about

Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis Lung disease in rheumatoid arthritis The multifaceted aspects of interstitial lung disease in rheumatoid arthritis A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease Smoking-related interstitial lung disease Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.The use of anti-TNFα medications for rheumatologic disease in pregnancy.Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients.Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.Association between anti-TNF-α therapy and interstitial lung disease.Rheumatoid arthritis-associated interstitial lung disease.Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?Unresolved issues in biologic therapy for rheumatoid arthritis.Overview of safety of non-biologic and biologic DMARDs.Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.The safety of biologic therapies in RA-associated interstitial lung disease.Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Lung Manifestations in the Rheumatic Diseases.Interstitial lung disease in rheumatoid arthritis in the era of biologics.Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis.Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery?Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.Pulmonary inflammation in mice with collagen-induced arthritis is conditioned by complete Freund's adjuvant and regulated by endogenous IFN-γ

P2860

Q26775753-92407584-4D86-4AED-9736-07E4C0A46017 Q26781712-BF1B9A3F-37A5-405F-910C-7F3523D46C93 Q26853575-FBF5DD08-20E2-46B4-98E1-E3A808A4FAE3 Q26861557-78713F9D-D12E-4EA6-BFA4-2DCCD0CBAD6B Q27014138-2009CCC4-C266-44DE-9B0C-4BCCC5F81D1A Q27027779-C60DCAEA-0397-4DD7-A457-F111D1B393EB Q28073436-000DA54A-5F1E-40D8-A364-262187D21FEB Q31039549-A49FF6C4-083C-425B-A8EC-ABB7F7DCE67E Q34272138-568ED5F2-E744-46CF-B36A-D1D39444B6DF Q34947978-206567D0-3F9F-4607-A18E-AE560DB1039B Q35029858-D9D84876-B366-4632-B6AA-635675CD67AA Q35176767-BC8ED385-F3CB-4D63-94A4-06B67422A985 Q35179712-49C01D2C-A9AD-4A8C-A222-F8922EE4B0BC Q35910779-0C47957F-9FC2-4D85-8F47-E79144863DDD Q36102004-CB03B2BB-83E5-4868-A5C8-11D4B5DFED6C Q36270376-044D715B-99FC-46C7-955E-F598D7B4EA52 Q36745669-F0794839-8504-4886-8B79-CEA80C54B220 Q37301130-58FAF384-134D-458F-A42B-4FDF7986BC77 Q37383148-24E89723-D856-4B2A-BF77-C05E7738C149 Q37586580-8A0E8893-89C3-4849-92AD-776DDC140023 Q37851001-B90FDAE8-F974-4024-9BCF-E7ED33931D40 Q38065768-89DB5925-0ABC-4FAA-A755-B0614FE76443 Q38125245-65E33BE5-8530-4B48-9C63-C831D3F766C8 Q38173669-76F0F9C5-C469-4B9A-8F15-A94247DF7424 Q38174219-A1538C54-6312-4A54-B348-20BB907BD158 Q38176745-A89F4C1F-68AC-4C73-9C59-8D909BADE202 Q38191199-78A635C8-C15A-4927-A9F4-31C0E8256A9E Q38658483-E58A4ACA-10D5-4D63-AAAB-7F2F52AD1BC7 Q38787176-EB5FAC29-B110-4641-8A0F-F8EA14C61D74 Q38819214-62D78728-3794-45DA-8617-37B4AC9C99C1 Q38979114-430010DB-FFC3-4F9A-8CB9-0D54FB2ACF7E Q39100810-A1AF949E-2F34-4AAE-9E27-BF4332C9370B Q39335156-C0D85EA5-FC5A-4590-B1B2-1401EB126A53 Q40136860-67BCDB76-CCB2-4302-A3EA-C4876B206D62 Q41687188-0E5C73BD-81D9-4539-9E1B-BD68EA19B41C Q45903141-7697E6BA-7E96-43F5-8C17-BD9F95E10034 Q46863441-AF7DBBF5-0D0C-4C9C-B346-F3C94606F355 Q47272022-D4786029-35E9-45CE-953B-D5553DB6561B Q48333831-AA30D9D6-4D1E-4354-9E2A-A6219DB8FC9C Q57010055-45D64ABD-2B55-40F8-8196-D6A0C1433A61

P2860

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

http://www.wikidata.org/entity/Q34110060

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Influence of anti-TNF therapy ...... heumatology Biologics Register

@ast

Influence of anti-TNF therapy ...... heumatology Biologics Register

@en

Influence of anti-TNF therapy ...... heumatology Biologics Register

@nl

type

label

Influence of anti-TNF therapy ...... heumatology Biologics Register

@ast

Influence of anti-TNF therapy ...... heumatology Biologics Register

@en

Influence of anti-TNF therapy ...... heumatology Biologics Register

@nl

prefLabel

Influence of anti-TNF therapy ...... heumatology Biologics Register

@ast

Influence of anti-TNF therapy ...... heumatology Biologics Register

@en

Influence of anti-TNF therapy ...... heumatology Biologics Register

@nl

P1433

Q34110060-A3342DF8-F648-4697-80CC-32B1E9FBDD48

P1476

Q34110060-5935A472-9C02-453A-9174-206E8FCF2907

P2093

Q34110060-274AAA19-ACCE-4AEC-B818-DB938E2ED551

Q34110060-4A4C607F-6C19-42D3-B910-F2A8B2B60641

Q34110060-5CEE56ED-0CCC-4667-9F57-497B80FAE350

Q34110060-CB985536-2230-4E40-8C1A-7C3BEF7DB46A

P2860

Q34110060-3DD4E80A-075D-48E5-BC24-4CE0AE80230A

Q34110060-4EF57F58-1680-42F9-A31B-0F4B634E1357

Q34110060-50A88443-E970-423A-A068-A0A2AC8A0958

Q34110060-6998BDA2-5760-40F4-BD07-DE5C1F884860

Q34110060-726D7FA1-ED40-42E0-B803-533E4842CEFA

Q34110060-752D396A-653D-4EDB-8856-91876300E1A4

Q34110060-87B2F67A-E126-4E53-9873-450DF958DBE8

Q34110060-913837EE-8098-4654-9D51-22546BFADC5A

Q34110060-982CD922-7287-4D14-B540-86142D948867

Q34110060-98B6D133-3213-4B34-BC1F-2BFDE1B48C66

P304

Q34110060-C7BCED5B-7F3A-4E7C-A5BB-26AC9EFA4127

P31

Q34110060-32A1A85C-2081-410A-8302-C6F304D83F1C

P356

Q34110060-6EDFB29B-238D-4271-ABF7-EC2E9FC0D3C4

P407

Q34110060-FC3A7356-B008-4AA7-94AB-39B370087D56

P433

Q34110060-5D65F194-948E-44C8-BF90-921A86EE7268

P478

Q34110060-A91A9151-33FC-4AA5-9D5F-55FFE874678E

P50

Q34110060-043FE02D-B829-4AFF-AAF6-5AC92B297FCA

Q34110060-6A16ABC0-8D27-4C58-9F83-5212DD350490

Q34110060-A18245CE-8ABD-4183-9356-482D6838C4B8

P577

Q34110060-B77FADAD-54C3-432D-9365-D64CE2B4DB17

P5875

Q34110060-969E8E05-4FCB-4617-9252-6A59766BAB97

P698

Q34110060-D9FFB922-E48C-49B5-B668-11E6CCD4F602

P921

Q34110060-041CDE2F-1FD5-4010-A1D7-7D7024F8CE87

Q34110060-6665F465-D42D-4436-89AA-9194A47DCE22

Q34110060-ECD44182-C2E9-4E24-91E5-F3CB70CDA4A7

P932

Q34110060-6C26048E-FED3-4074-B9C6-0A1B99BF3423

P356

ARD.2009.120626

P1433

Annals of the Rheumatic Diseases

P1476

Influence of anti-TNF therapy ...... heumatology Biologics Register

@en

P2093

BSRBR Control Centre Consortium

http://www.w3.org/2001/XMLSchema#string

British Society for Rheumatology Biologics Register

http://www.w3.org/2001/XMLSchema#string

K D Watson

http://www.w3.org/2001/XMLSchema#string

K L Hyrich

http://www.w3.org/2001/XMLSchema#string

P2860

Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis

The British Society for Rheumatology biologics register.

Interstitial lung disease in rheumatoid arthritis: recent advances.

The controversial role of tumor necrosis factor alpha in fibrotic diseases.

Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab.

Subclinical alveolitis in immunological systemic disorders. Transition between health and disease?

P304

1086-1091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2009.120626

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Deborah P.M. Symmons

P577

2010-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44575356

http://www.w3.org/2001/XMLSchema#string

P698

20444754

http://www.w3.org/2001/XMLSchema#string

P921

P932

2935328

http://www.w3.org/2001/XMLSchema#string